BPC 157 Protects the Liver From Multiple Types of Damage — Even When Taken Orally
BPC 157 prevented liver necrosis in three different injury models and outperformed bromocriptine, amantadine, and somatostatin — effective both orally and by injection.
Quick Facts
What This Study Found
BPC 157 prevented liver necrosis and fatty changes in bile duct ligation, restraint stress, and CCl4 models. Effective orally and intraperitoneally. Outperformed bromocriptine, amantadine, and somatostatin.
Key Numbers
How They Did This
Rats were subjected to bile duct + hepatic artery ligation, 48-hour restraint stress, or CCl4 administration. BPC 157 was given intragastrically or intraperitoneally. Liver tissue was examined histologically.
Why This Research Matters
BPC 157's liver protection across multiple injury types suggests a broad protective mechanism. Its oral effectiveness is especially important because it means the peptide could be taken as a pill.
The Bigger Picture
Liver damage from stress, toxins, and surgical complications is a major medical problem. A peptide that protects the liver across multiple injury types — and works orally — could become a significant therapeutic tool.
What This Study Doesn't Tell Us
Animal study in rats. Three acute/subacute injury models may not represent chronic liver disease. Mechanism of protection not identified. No dose-response data presented in abstract.
Questions This Raises
- ?What is BPC 157's mechanism of liver protection?
- ?Would these results translate to human liver disease?
Trust & Context
- Key Stat:
- Outperformed 3 reference drugs BPC 157 provided better liver protection than bromocriptine, amantadine, and somatostatin across all three injury models
- Evidence Grade:
- Moderate — animal study with multiple injury models and active comparators. Strengthened by cross-model consistency, limited by lack of human data.
- Study Age:
- Published in 1993 (33 years ago). BPC 157 continues to be studied for its multi-organ protective properties.
- Original Title:
- Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.
- Published In:
- Life sciences, 53(18), PL291-6 (1993)
- Authors:
- Sikiric, P(36), Seiwerth, S(42), Grabarevic, Z(12), Rucman, R, Petek, M, Rotkvic, I, Turkovic, B, Jagic, V, Mildner, B, Duvnjak, M
- Database ID:
- RPEP-00278
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is BPC 157?
BPC 157 (Body Protection Compound) is a 15-amino-acid peptide originally discovered in gastric juice. It shows protective effects on multiple organs including the stomach, liver, and tendons.
Why is oral effectiveness important?
Most peptides are destroyed in the stomach and cannot be taken as pills. BPC 157's ability to work orally makes it potentially practical as a medication, unlike most peptide drugs that require injection.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00278APA
Sikiric, P; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Rotkvic, I; Turkovic, B; Jagic, V; Mildner, B; Duvnjak, M. (1993). Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.. Life sciences, 53(18), PL291-6.
MLA
Sikiric, P, et al. "Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.." Life sciences, 1993.
RethinkPeptides
RethinkPeptides Research Database. "Hepatoprotective effect of BPC 157, a 15-amino acid peptide,..." RPEP-00278. Retrieved from https://rethinkpeptides.com/research/sikiric-1993-hepatoprotective-effect-of-bpc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.